Romidepsin (FK228, Depsipeptide)

For research use only. Not for use in humans.

目录号:S3020 别名: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。

规格 价格 库存 购买数量  
RMB 1285.83 现货
RMB 3910.79 现货
RMB 5710.89 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Romidepsin (FK228, Depsipeptide)发表文献97篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。
特性 Romidepsin对I型HDAC的抑制作用明显强于对II型HDAC的抑制。
靶点
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外研究

Romidepsin抑制NSCLC细胞系生长,IC50范围从1.3 ng/mL到4.9 ng/mL。 Romidepsin可以降低Erlotinib对NSCLC细胞系的IC50值, 增加NSCLC细胞系对Erlotinib的敏感性[1]。Romidepsin处理72小时可以抑制6/6 人 NB 肿瘤细胞系的生长,而 NIH3T3细胞系并不受影响。 Romidepsin对于单拷贝或N-myc 多拷贝的NB细胞系以及含有正常或突变的p53 和含有Alk突变体的细胞系都有选择性的细胞毒性,这种毒性具有剂量依赖的特性。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 MUDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NH6wVXozNjVvMUWgcm0> M1HPb|czKGh? MmjvbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MmPRNlU4QTB7MEe=
U2932  M3fub2NmdGxiVnnhZoltcXS7IFHzd4F6 MnjuNk42NTF3IH7N MlvrO|IhcA>? MVHpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MU[yOVc6ODlyNx?=
OCI-LY7 M1\yNWNmdGxiVnnhZoltcXS7IFHzd4F6 MXuyMlUuOTVibl2= NUTtbpdUPzJiaB?= MV3pcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MlHQNlU4QTB7MEe=
Farage MmTER4VtdCCYaXHibYxqfHliQYPzZZk> MnHlNk42NTF3IH7N NHz4[W84OiCq NE\JTWlqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi M3XMZ|I2PzlyOUC3
LY7/EBV MnfvR4VtdCCYaXHibYxqfHliQYPzZZk> MoHQNk42NTF3IH7N MVu3NkBp NImyZZpqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NYW0RlZyOjV5OUC5NFc>
U2932/EBV NXrJdms3S2WubDDWbYFjcWyrdImgRZN{[Xl? MY[yMlUuOTVibl2= MWO3NkBp M{TLTolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NWLwW5pNOjV5OUC5NFc>
HCT116 NGfP[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrsc482NTVyMECgcm0> NEfadG0zPCCq NWO4SotSTE2VTx?= NUmzb3M{cW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M{ns[FI2PDl{NUG1
ACH-2 NYHNTZVpTnWwY4Tpc44hSXO|YYm= M4PjcFEuQSCwTR?= NYHJSVRbOjRiaB?= NIrSUYlqdmS3Y3XzJGhKXi1zIFXuekBmgHC{ZYPzbY9v NEPhR3czPTF2OUS2Oy=>
MCF-10A NYnESoVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPD[W9wUUN3ME2wMlE4yrFyLkCxJI5O NVjofFl7OjR7NUS4OVY>
MCF-7 NFfVfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHlN3pKSzVyPUGuNVDDuTBwMkCgcm0> NF2yV20zPDl3NEi1Oi=>
SK-BR-3 M4r6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwMEFCtVAvOzVibl2= NGnGOpMzPDl3NEi1Oi=>
MDA-MB-231 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwNklCtVAvOTRibl2= M4XpVlI1QTV2OEW2
PC3 MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHXWZBKSzVyPUGuOlXDuTBwM{Wgcm0> MYOyOFk2PDh3Nh?=
HCT116 MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFwMEFCtVAvODBibl2= NXHxd5V7OjR7NUS4OVY>
HCT116-p21-/- MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHkSYpKSzVyPUGuNlbDuTBwM{egcm0> M4TVV|I1QTV2OEW2
S1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTdwNkhCtVAvOjlibl2= MYKyOFk2PDh3Nh?=
SW620 M{XNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwOURCtVAvOjlibl2= MmC0NlQ6PTR6NU[=
LOX-IMVI NHTaeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwOEhCtVAvODNibl2= NEmy[XUzPDl3NEi1Oi=>
UACC-62 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwNUdCtVAvOTZibl2= MV2yOFk2PDh3Nh?=
MDA-MB-435 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi0ZZFKSzVyPUCuPVDDuTBwME[gcm0> NIP3TmIzPDl3NEi1Oi=>
SF-295 NUPWfYRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwOElCtVAvOTVibl2= MWeyOFk2PDh3Nh?=
A549 NYDlOlI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFwMkdCtVAvOjRibl2= MmTnNlQ6PTR6NU[=
H460 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3XOI5KSzVyPUKuOVjDuTBwOECgcm0> M3fieVI1QTV2OEW2
EKVX NHnPcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTFwM{RCtVAvOzRibl2= M2rlR|I1QTV2OEW2
H146 MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\FTWM2OD1yLkKyxtExNjB5IH7N MXGyOFk2PDh3Nh?=
H526 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvwN3NPUUN3ME2wMlE2yrFyLkCzJI5O MX6yOFk2PDh3Nh?=
HuT-78 MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHFTmd[UUN3ME2xMlc{yrFyLkS0JI5O NVrPW2VNOjR7NUS4OVY>
HA M1\jSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TVRVAvPjJ3LUGwcm0> MU[0PEBp MnzBbY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> NVfM[nJrOjR5N{G1NVA>
MS-275 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWiwMlYzPS1zMH7N NYXaPGoyPDhiaB?= NHn6[mpqdmS3Y3XzJIEhe2mpbnnmbYNidnSueTDzeJJwdmencjDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifGWmIIfpeIgh[m:{dHX6c41q[g>? M1:xPVI1PzdzNUGw
CD4 T MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[0PEBp NH\VO5NGSzVyPUSuOeKyOS5yIH7N MmHxNlQ4OjJ2NUS=
CD4 T MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHiUYNCPDhiaB?= NX7rUI5KS0N3ME2xNFfDuTF{NjDuUS=> M{LtN|I1PzJ{NEW0
CD4+ T NGPDclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnmRoZGSzVyPUOgcm0> NHnDRYkzPDR7NUGwOS=>
A549 NWT1bIVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXISlk5OTEkgKOxNFDDqG6P NVvNelI4OjRxM{[vOFghcA>? MlrkbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NXzncJd5OjR2OEW3PVk>
JJN3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELiRoEzPC92ODDo M4X6RWVEPTB:MfMAjY5OQyB2OPMAjYg> NXTGeYdqOjRyM{CxOVA>
OPM-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL1Z44zPC92ODDo MYPFR|Uxez1z4pEJcm08KDR64pEJbC=> MWSyOFA{ODF3MB?=
RPMI-8226 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL2SGUzPC92ODDo MnjrSWM2OHN;MT645qCKdk19IES45qCKcA>? MUWyOFA{ODF3MB?=
U266 M3\uXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XvPFI1NzR6IHi= M3rOSGVEPTC|PUGw5qCKdk19IES45qCKcA>? MYeyOFA{ODF3MB?=
CA46 NHPr[YdCeG:ydH;zbZMhSXO|YYm= M2frcVYhcA>? NVvZSFYzcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NWHn[5pNOjN7Nk[xOlQ>
DG75 M4XidGFxd3C2b4Ppd{BCe3OjeR?= MorEOkBp MVrpcoR2[2W|IH7vJIFxd3C2b4Ppdy=> M{PiNlI{QTZ4MU[0
Ramos MkCxRZBweHSxc3nzJGF{e2G7 MnH1OkBp NXy2OHJScW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ M3zu[FI{QTZ4MU[0
ST486 NXP2dJpHSXCxcITvd4l{KEG|c3H5 Ml63OkBp NHq1b4JqdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> M2\QXFI{QTZ4MU[0
HuT78 Mle3RZBweHSxc3nzJGF{e2G7 NUC2TWRnOS9zMD:xNFAhdk1? NGi0OZk1QCCq NVPnNpNUcW6mdXPld{BieG:ydH;zbZMh[XRiMTDuUS=> MUKyN|U{Ojd|Mh?=
DpVp35 MYfBdI9xfG:|aYOgRZN{[Xl? NVLMVmNCOS9zMD:xNFAhdk1? M3\GW|Q5KGh? NYDWW5ptcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NHHzb4QzOzV|MkezNi=>
DpVp50 NEHmZnpCeG:ydH;zbZMhSXO|YYm= NGjSbW4yNzFyL{GwNEBvVQ>? M1HyeVQ5KGh? NWrPOmJGcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= Ml\FNlM2OzJ5M{K=
DpP75  MX\BdI9xfG:|aYOgRZN{[Xl? Mom4NU8yOC9zMECgcm0> Mn;kOFghcA>? NV2zN457cW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= MX[yN|U{Ojd|Mh?=
SKOV-3 NYnkNlI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX34OIE2OeLCk{Kwcm0> MXG3NkBp NFfhSGRFVVOR NHf2N49z\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NH;OSo4zOzBzMEO0PC=>
Brca1 WT NHXzTVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLxNgKBmzJybl2= NF6xVZE4OiCq M2CyRmROW09? NEfHWWhz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NYrETIlWOjNyMUCzOFg>
Brca1 Null MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6x5qCUOjCwTR?= NVHSSmpjPzJiaB?= NY\reXlzTE2VTx?= MlT4doVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MXWyN|AyODN2OB?=
OVCAR-8  M3vPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DCSlHjiJN{MH7N NIjZS|g4OiCq MWnEUXNQ NWTpSodtemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? M1jxXlI{ODFyM{S4
NCI/ADR-RES M3izRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX2x5qCUOjCwTR?= NG\UTJY4OiCq NGm5W2pFVVOR MoHwdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MVKyN|AyODN2OB?=
HCT116 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHOcFhGPSCwTT21NEDPxE1? M4PYS|I1KGh? MVzEUXNQ M4TEO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NHfVXZYzOjl{NEm1PC=>
RKO NWDSeIp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFy4Smo2KG6PLUWwJO69VQ>? M1PBclI1KGh? NVXjbFZETE2VTx?= Mk[zbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MV[yNlkzPDl3OB?=
CO115 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPjdJFzPSCwTT21NEDPxE1? NFz5bVYzPCCq NWe4PJVITE2VTx?= M1\idIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MV:yNlkzPDl3OB?=
HFS MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLjOUBvVQ>? Mn3oNlQwPDhxN{KgbC=> NFfuXWhqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 NETjTHYzOjFyNkK4Ni=>
LNCaP NHHHeYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\SXpl2PSCwTR?= M{Xn[|I1NzR6L{eyJIg> Mk[4bY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> Mo\MNlIyODZ{OEK=
A549 NIqxTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlP0OUBvVQ>? Mn3qNlQwPDhxN{KgbC=> MnjPbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> NHLxUFczOjFyNkK4Ni=>
697  Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHZTWM2OOLCiU5ihKkzNjYEoH7N NECz[3ozOTV|OEKxOi=>
697-R M2jN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfHNGJKSzVy4pEJQgKBkThwNtMgcm3DqA>? MVeyNVU{QDJzNh?=
HUT78 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFibl2= Moj3NlEyQTh3NEW=
THJ-16T NXrx[o1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSxJI5O MnL0NlQhcA>? MVnpcohq[mm2czDj[YxtKGe{b4f0bC=> MknvNlA5OTB3Nki=
HCT116 MVHGeY5kfGmxbjDBd5NigQ>? MWeyNEBvVQ>? NHzBbJE5KGh? M3PZO41w\HWuYYTld{B1emGwc3PybZB1KGyndnXsd{Bnd3JiaIXu[JJm\HNib3[g[4Vv\XNiaX6g[Yl1cGW{IHTpdoVkfGmxbh?= M4fRXVIxPzN7NEW0
B104  MlHhSpVv[3Srb36gRZN{[Xl? M4DP[VIhdk1? M3O1OlI1NzR6L{eyJIg> M17QOolv[3KnYYPld{B1cGVic4Xy[oFk\SCneIDy[ZN{cW:wIH;mJGNFOjEEoB?= NUPIbnVtOjB4OE[1NFU>
HL-60  NH3MO|VEgXSxdH;4bYNqfHliQYPzZZk> MUOxMVUxOCCwTR?= MofSNlQhcA>? MWDpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MX2yNFYzPDF4Mx?=
HP100 M2TPRWN6fG:2b4jpZ4l1gSCDc4PhfS=> NHHUWWoyNTVyMDDuUS=> NFH4[Y8zPCCq NFHJVIVqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MUmyNFYzPDF4Mx?=
HL-60  NEHIUIlHfW6ldHnvckBCe3OjeR?= NF3mem0yOCCwTR?= MWq0M|YwOTZiaB?= NGrTSJVqdmS3Y3XzJJRp\SCpZX7ldoF1cW:wIH;mJIh6\HKxZ3XuJJBmem:6aXTlJIZzd21iNHi= Mo\5NlA3OjRzNkO=
HP100 NXvkWVVPTnWwY4Tpc44hSXO|YYm= MnrQNVAhdk1? NFPVRno1NzZxMU[gbC=> M2TLbIlv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= NUfCRVRMOjB4MkSxOlM>
HL-60  M1e4TmZ2dmO2aX;uJGF{e2G7 M13MelExNTVyMDDuUS=> NEi2Tm81KGh? M4\ReIRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= MknKNlA3OjRzNkO=
HP100 NFrHRWdHfW6ldHnvckBCe3OjeR?= NYrjSlFFOTBvNUCwJI5O MknnOEBp NVz4dmh2\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg M3\meVIxPjJ2MU[z
11z NF;0TGlMcW6jc3WgRZN{[Xl? MW[zMVExOCCwTR?= NFy5SXZz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= MVOyNFYxPTF2NB?=
SKOV-3 MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYW0M|gwOTZibl2= NVr0SWNoPDhiaB?= MmnabY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> M3zOT|IxPDB2NU[0
OVCAR-3 NV7QNmhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYq0M|gwOTZibl2= Mk\EOFghcA>? M4\FTIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MorXNlA1ODR3NkS=
HBL-2 NF;NelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:yMVExKG6P MnrHNlQhcA>? MYfJR|UxRTRwMzDuUS=> NF;PUGMzODB4OEC4NC=>
Jeko-1 MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojNNk02OCCwTR?= NIqzWHIzPCCq MYTJR|UxRTFzIH7N MX[yNFA3QDB6MB?=
Granta-519 NGi0TpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH2OU01OCCwTR?= MX:yOEBp MVXJR|UxRTV6LkWgcm0> NV;Gb2o4OjByNkiwPFA>
L1236 M4K0VGN6fG:2b4jpZ4l1gSCDc4PhfS=> M2DROVEhdk1vMUCwJO69VQ>? NHzTWnA1QCCq NWnxd3dHTUN3ME2wMlA4KM7:TR?= Mln0NVkzOzN2N{C=
L428 MnvVR5l1d3SxeHnjbZR6KEG|c3H5 MWCxJI5ONTFyMDFOwG0> NGfUU2o1QCCq NUHBfZY{TUN3ME2wMlQ{KM7:TR?= MWixPVI{OzR5MB?=
KM-H2 NFLkeZJEgXSxdH;4bYNqfHliQYPzZZk> MWSxJI5ONTFyMDFOwG0> M{nESlQ5KGh? MnjlSWM2OD1yLkW4JO69VQ>? MmG0NVkzOzN2N{C=
L540Cy MYLDfZRwfG:6aXPpeJkhSXO|YYm= MWexJI5ONTFyMDFOwG0> MXm0PEBp MnfuSWM2OD1yLkG2JO69VQ>? NI\TZ2YyQTJ|M{S3NC=>
G401 MYLGeY5kfGmxbjDBd5NigQ>? M4LWSlExKG6P MXOyOE81QC95MjDo MnjDSG1UVw>? MmD3bY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u Ml72NVkzOjF3OE[=
STM91-01 MknDSpVv[3Srb36gRZN{[Xl? NHHscJoyOCCwTR?= M1G2b|I1NzR6L{eyJIg> NWHpWY1PTE2VTx?= M3X3[Ilv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> MVGxPVIzOTV6Nh?=
SJSC  M4PVOWZ2dmO2aX;uJGF{e2G7 MWWxNEBvVQ>? NXfVOHBWOjRxNEivO|IhcA>? NYTiNIhCTE2VTx?= NGD4PIlqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> M3XReFE6OjJzNUi2
BT16  Ml3iSpVv[3Srb36gRZN{[Xl? NXi2PVFIOTBibl2= MoHoNlQwPDhxN{KgbC=> NGrtWZRFVVOR MUnpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= M4HidlE6OjJzNUi2
NCI-H1299 M3nRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPzTWM2OD12LkdCtVAvOiCwZz;tcC=> MV[xPVE4QTh7MB?=
NCI-2882 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHqydJlKSzVyPUGuOuKyOC5yNDDu[{9udA>? NVfIeGpjOTlzN{m4PVA>
HCC95 NHTVfndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\LTWM2OD1{LkZCtVAvODVibnevcYw> NV3mWllCOTlzN{m4PVA>
NCI-H23 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fzVmlEPTB;Mj65xtExNjJibnevcYw> NY\wOYxrOTlzN{m4PVA>
NCI-H157 NXvp[mF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGybIpKSzVyPUGuOuKyOC5yMjDu[{9udA>? NX7ke|NjOTlzN{m4PVA>
NCI-H460 NUjYNopxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJwMdMxNE4xPyCwZz;tcC=> MlrsNVkyPzl6OUC=
NCI-H1975 MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nBR2lEPTB;MT6zxtExNjB2IH7nM41t MWixPVE4QTh7MB?=
NCI-H820 Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHmN2I5UUN3ME2yMlTDuTBwMTDu[{9udA>? M3LXbVE6OTd7OEmw
NCI-H1650 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInYXWNKSzVyPUSuPeKyOC5|IH7nM41t M2L1R|E6OTd7OEmw
DTC1 NFf6NIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwNUGgcm0> NXvOV2tjOTh3Nk[yOFY>
KAO NEno[|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{W4N2lEPTB;MD65NUBvVQ>? NGHMeWQyQDV4NkK0Oi=>
SU-CCS-1 Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwOEmgcm0> Ml7UNVg2PjZ{NE[=
SYO-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DZRmlEPTB;MD62O{BvVQ>? Mn3LNVg2PjZ{NE[=
FUJI NHnib2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTq[5JKSzVyPUGuN|Ehdk1? NYK0RZZoOTh3Nk[yOFY>
SKNMC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwMUegcm0> NVnRTo9vOTh3Nk[yOFY>
402-91 NVztepZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PJbWlEPTB;MT6yOkBvVQ>? MVyxPFU3PjJ2Nh?=
1765-92 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\jeVZ4UUN3ME2xMlc4KG6P MlLQNVg2PjZ{NE[=
JN-DSRCT-1 MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XITGlEPTB;MT6yOUBvVQ>? M2SwelE5PTZ4MkS2
NMS-2PC M3\Ob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPHepRKSzVyPUCuPFEhdk1? MY[xPFU3PjJ2Nh?=
HL60 Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G3WmlEPTB;MT64OkBvVQ>? Mn;4NVg2PjZ{NE[=
A549 M4T0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTNwMkSgcm0> MXyxPFU3PjJ2Nh?=
SW480 NWG0OXpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7zTWM2OD1{Lk[5JI5O M3nqVVE5PTZ4MkS2
MCF7 M3PmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\LN2lEPTB;Mz61OUBvVQ>? M2\Sb|E5PTZ4MkS2
PC-3 NV7LXoZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJwNUGgcm0> NIXzUI4yQDV4NkK0Oi=>
MMRU MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTJwNUegcm0> MWexPFU3PjJ2Nh?=
Hs68 NFm3[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFe5[mVKSzVyPU6xNEBvVQ>? M2HibVE5PTZ4MkS2
hMSC-001F MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRT5zMDDuUS=> NWXWTHAzOTh3Nk[yOFY>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p21 / Cyclin D1; 

PubMed: 19682393     


NIH 3T3 cells stably expressing the indicated proteins were treated with DMSO (Vehicle) or the indicated concentration of romidepsin for 24 h. Cell lysates were analyzed by western blotting with antibodies to cyclin D1, p21 and β-actin (loading control). Data shown are representative of at least two independent experiments.

AcH3(K9) / Ac-α-Tubulin(K40) / Ac-NFκB2(K310) p65 / 3MeH3(K27); 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

HDAC3 / HDAC4 / HDAC6 / HDAC2; 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

γH2AX / PARP1 / Cleaved caspase3 / BAK / p21(waf1/cip1) / XIAP; 

PubMed: 26473529     


Western blot analysis of proteins involved in DNA-damage response and apoptosis. Established cell lines were exposed to different concentrations of romidepsin (Rom) for 48 h and total cell extracts were analyzed.

Cyclin E1 / BRCA1 / E2F1 / Cleaved PARP / H3Ac; 

PubMed: 27444036     


Western blot analysis of the effects of panobinostat (25 nM), vorinostat (5 µM) and romidepsin (10 nM) on expression of cyclin E1, E2F1, BRCA1, cleaved PARP and acetylated histone H3 in OVCAR-3 cells. Actin and histone H3 were loading controls. 

pAKT(S473) / pAKT(T308) / AKT; 

PubMed: 25492515     


Western blot analysis of phosphorylated AKT in PC3 cells. Cells were treated for 3 h with various concentrations of FK228. 

19682393 26473529 27444036 25492515
Growth inhibition assay
Cell viability; 

PubMed: 27444036     


Concentration-dependent effects of panobinostat and vorinostat in SRB viability assays in OVCAR-3 cells (72 h). Values are mean+SE of 3 independent experiments. 

27444036
Immunofluorescence
SS18/TLE1; 

PubMed: 27120803     


A significant decrease in detectable PLA signal following HDAC inhibition in SYO-1 cells.

Cleaved caspase-3; 

PubMed: 22531354     


TDP-B activates cleaved caspase-3 by immunofluorescence. Representative immunofluorescence staining for cleaved caspase 3 (green) in SKOV-3 ovarian cancer cells treated with 10 nM FK228, TDP-A or TDP-B after 24 h of exposure. The nuclei are stained with DAPI (blue).

27120803 22531354
体内研究 与PBS处理的对照组相比,单独使用Erlotinib 和 Romidepsin分别可以对NCI-H1299细胞系的异种移植生长抑制到72% 和 43% ,但是并不具有明显的统计学意义。只有当两种药物联用的时候才会对其生长造成明显的抑制作用,此时生长被抑制到28% [1]。在免疫功能低下的小鼠中,Romidepsin 会抑制皮下NB 异种移植的生长,这种抑制作用具有剂量依赖的特性 。此外, 在NB病人的肿瘤组织中Romidepsin 会诱导某些基因的表达,如 p21 和p75 以及NTRK (TrkA) [2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
细胞实验:[3]
- 合并
  • Cell lines: NCI-H1975, NCI-H157, NCI-2882, NCI-H460 和 HCC95 细胞系
  • Concentrations: 1 ng/mL
  • Incubation Time: 72 小时
  • Method: 使用MTS法分析药物敏感性。在96孔平板中每孔接种2×103个细胞(包括NCI-H1975, NCI-H157, NCI-2882, NCI-H460和HCC95) 。24小时后, 在存在或者缺少1 ng/mL Romidepsin的条件下将细胞与不同浓度 (0.01 µM - 250 µM) 的Erlotinib 37°C 孵育72 小时。 MTS 溶液加到每个孔中37°C孵育1小时。利用分光光度计测量490 nm 处的光密度值。每种药物浓度的实验都设置8个复孔并重复两次。基于细胞生存曲线的吸光度值计算药物的半抑制浓度 (IC50) 。
    (Only for Reference)
动物实验:[5]
- 合并
  • Animal Models: 携带NCI-H1299 细胞的 BALB/c无胸腺裸小鼠
  • Formulation: 用PBS配制
  • Dosages: 1.2 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 540.7
化学式

C24H36N4O6S2

CAS号 128517-07-7
储存条件 粉状
溶于溶剂
别名 FR 901228, NSC 630176

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03770000 Recruiting Drug: Tenalisib|Drug: Romidepsin T Cell Lymphoma Rhizen Pharmaceuticals SA March 12 2019 Phase 1|Phase 2
NCT02616965 Recruiting Drug: Romidepsin|Drug: Brentuximab vedotin Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics Inc.|Celgene Corporation February 22 2017 Phase 1
NCT02616874 Completed Drug: MVA.HIVconsv vaccine|Drug: Romidepsin HIV IrsiCaixa|Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA|Hospital Clinic of Barcelona|Hospital de Sant Pau|HIVACAT|University of Oxford|BCN Checkpoint February 2016 Phase 1
NCT03141203 Recruiting Drug: Romidepsin|Drug: Carfilzomib Peripheral T Cell Lymphoma University of Birmingham|Bloodwise|Celgene|Amgen July 13 2015 Phase 1|Phase 2
NCT02393794 Recruiting Drug: Romidepsin|Drug: Cisplatin|Drug: Nivolumab Triple-Negative Breast Cancer|Breast Cancer Priyanka Sharma|Celgene Corporation|Bristol-Myers Squibb|University of Kansas Medical Center July 17 2015 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)供应商 | 采购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)价格 | Romidepsin (FK228, Depsipeptide)生产 | 订购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID